NASDAQ:ZLAB - Zai Lab Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$16.47 -0.52 (-3.06 %)
(As of 10/19/2018 04:49 AM ET)
Previous Close$16.99
Today's Range$16.18 - $16.87
52-Week Range$14.29 - $30.16
Volume69,400 shs
Average Volume130,160 shs
Market Capitalization$1.13 billion
P/E Ratio-7.10
Dividend YieldN/A
BetaN/A
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC. The company's drug candidates also comprise ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; and ZL-2302 to treat non-small cell lung cancer. The company, through its subsidiary, Zai Lab (Shanghai) Co. Ltd., has a collaboration agreement with the NovoCure Limited to perform clinical studies, sell, and import tumor treating field products in the field of oncology. Zai Lab Limited was founded in 2013 and is headquartered in Shanghai, the People's Republic of China.

Receive ZLAB News and Ratings via Email

Sign-up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ZLAB
CUSIPN/A
Phone86-21-6163-2588

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-7.10
Forward P/E Ratio-9.25
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.77 per share
Price / Book3.45

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees52
Outstanding Shares58,100,000
Market Cap$1.13 billion

Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions

What is Zai Lab's stock symbol?

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

What price target have analysts set for ZLAB?

2 equities research analysts have issued 1-year target prices for Zai Lab's shares. Their predictions range from $32.00 to $43.00. On average, they anticipate Zai Lab's share price to reach $37.50 in the next twelve months. This suggests a possible upside of 127.7% from the stock's current price. View Analyst Price Targets for Zai Lab.

What is the consensus analysts' recommendation for Zai Lab?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zai Lab.

Who are some of Zai Lab's key competitors?

Who are Zai Lab's key executives?

Zai Lab's management team includes the folowing people:
  • Dr. Ying Du, Chairman & CEO (Age 52)
  • Mr. Ki Chul Cho, Chief Financial Officer (Age 41)
  • Dr. Ning Xu, Exec. VP of Clinical Operations & Regulatory Affairs (Age 53)
  • Dr. Qi Liu, Chief Medical Officer of Oncology (Age 53)
  • Dr. James Yan, Exec. VP, Head of Early Devel. & Drug Safety (Age 54)

When did Zai Lab IPO?

(ZLAB) raised $100 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.

Who are Zai Lab's major shareholders?

Zai Lab's stock is owned by many different of institutional and retail investors. Top institutional investors include Bank of Montreal Can (0.01%).

Which institutional investors are buying Zai Lab stock?

ZLAB stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can.

How do I buy shares of Zai Lab?

Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zai Lab's stock price today?

One share of ZLAB stock can currently be purchased for approximately $16.47.

How big of a company is Zai Lab?

Zai Lab has a market capitalization of $1.13 billion. The company earns $-50,380,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis. Zai Lab employs 52 workers across the globe.

What is Zai Lab's official website?

The official website for Zai Lab is http://www.zailaboratory.com.

How can I contact Zai Lab?

Zai Lab's mailing address is 1043 HALEI ROAD ZHANGJIANG HI-TECH PARK, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6163-2588 or via email at [email protected]


MarketBeat Community Rating for Zai Lab (NASDAQ ZLAB)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  104 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  238
MarketBeat's community ratings are surveys of what our community members think about Zai Lab and other stocks. Vote "Outperform" if you believe ZLAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZLAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel